Suppr超能文献

Fraser 健康肾脏计划血液透析患者钙化防御风险因素的特征-一项匹配病例对照回顾性研究。

Characterization of Risk Factors for Calciphylaxis in Hemodialysis Patients in the Fraser Health Renal Program - A Matched Case-Control Retrospective Review.

机构信息

Department of Pharmacy, Burnaby Hospital, Burnaby, BC, Canada.

Department of Pharmacy, Royal Columbian Hospital, New Westminster, BC, Canada.

出版信息

J Pharm Pract. 2023 Dec;36(6):1424-1437. doi: 10.1177/08971900221118444. Epub 2022 Aug 28.

Abstract

Calciphylaxis is a lethal and rare disease characterized by ischemic and necrotic skin lesions caused by vascular calcification of adipose tissue. There have been many risk factors analyzed in the literature; however, the pathogenesis of calciphylaxis is still not well understood and treatment options are limited due to the lack of interventional studies. Our objectives were to describe risk factors, prevalence, incidence, and outcomes for calciphylaxis in hemodialysis patients within the Fraser Health Renal Program. This was a retrospective matched case-control study of hemodialysis patients within the Fraser Health Renal Program. Hemodialysis patients with calciphylaxis were matched to hemodialysis patients without calciphylaxis in a 1:2 ratio for age and sex from September 2, 2017 to July 3, 2020. There was a total of 40 calciphylaxis cases matched to 80 controls. In the univariate analysis, peritoneal dialysis, higher body mass index, lower serum iron, lower transferrin saturation, sevelamer, cinacalcet, warfarin, iron (PO), and insulin were associated with increased risk of calciphylaxis. In the multivariate analysis, only peritoneal dialysis, serum iron, sevelamer, and warfarin were identified as significant and strong risk factors associated with calciphylaxis. A low prevalence of 1.9% and high mortality rate of 57.5% at 12 months was found for calciphylaxis cases. Significant risk factors associated with calciphylaxis were peritoneal dialysis, serum iron, sevelamer, and warfarin. Future studies should further investigate the impact of minimizing exposure to these risk factors to reduce calciphylaxis development.

摘要

钙化防御是一种罕见且致命的疾病,其特征为脂肪组织血管钙化导致的缺血性和坏死性皮肤损伤。文献中已经分析了许多风险因素;然而,由于缺乏干预性研究,钙化防御的发病机制仍未得到很好的理解,治疗选择也有限。我们的目的是描述弗雷泽健康肾脏计划中血液透析患者的钙化防御的风险因素、患病率、发病率和结局。这是弗雷泽健康肾脏计划中血液透析患者的回顾性匹配病例对照研究。2017 年 9 月 2 日至 2020 年 7 月 3 日,我们将钙化防御的血液透析患者与钙化防御的血液透析患者按年龄和性别 1:2 进行匹配。共有 40 例钙化防御病例与 80 例对照匹配。单因素分析显示,腹膜透析、较高的体重指数、较低的血清铁、较低的转铁蛋白饱和度、司维拉姆、西那卡塞、华法林、铁(PO)和胰岛素与钙化防御的风险增加相关。多因素分析显示,只有腹膜透析、血清铁、司维拉姆和华法林被确定为与钙化防御显著相关的强风险因素。钙化防御的患病率为 1.9%,12 个月的死亡率为 57.5%,这一结果表明钙化防御的患病率较低,死亡率较高。与钙化防御相关的显著风险因素包括腹膜透析、血清铁、司维拉姆和华法林。未来的研究应进一步探讨尽量减少接触这些风险因素以减少钙化防御发展的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验